Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy.

Tannen RL, Weiner MG, Xie D, Barnhart K.

Hum Reprod. 2007 Jun;22(6):1769-77.

2.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL.

J Natl Cancer Inst. 2013 Apr 17;105(8):526-35. doi: 10.1093/jnci/djt043.

3.

Hormone therapy and coronary heart disease in young women.

Weiner MG, Barnhart K, Xie D, Tannen RL.

Menopause. 2008 Jan-Feb;15(1):86-93.

PMID:
17502840
4.

A simulation using data from a primary care practice database closely replicated the women's health initiative trial.

Tannen RL, Weiner MG, Xie D, Barnhart K.

J Clin Epidemiol. 2007 Jul;60(7):686-95.

PMID:
17573984
5.

Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index.

Chlebowski RT, Anderson GL, Aragaki AK, Prentice R.

J Natl Cancer Inst. 2015 Nov 5;108(2). pii: djv327. doi: 10.1093/jnci/djv327. Review.

PMID:
26546117
6.

Changing concepts: Menopausal hormone therapy and breast cancer.

Chlebowski RT, Anderson GL.

J Natl Cancer Inst. 2012 Apr 4;104(7):517-27. doi: 10.1093/jnci/djs014. Review.

7.

The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.

Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F.

J Steroid Biochem Mol Biol. 2014 Jul;142:4-11. doi: 10.1016/j.jsbmb.2013.10.009. Review.

PMID:
24172877
8.

Estrogen plus progestin and risk of benign proliferative breast disease.

Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2337-43. doi: 10.1158/1055-9965.EPI-08-0380.

9.

Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.

Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, Rodabough RJ, Johnson KC, Wactawski-Wende J, Kotchen JM, Ockene JK, O'Sullivan MJ, Hubbell FA, Chien JW, Chen C, Stefanick ML.

J Natl Cancer Inst. 2010 Sep 22;102(18):1413-21. doi: 10.1093/jnci/djq285.

10.

Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.

Lacey JV Jr, Leitzmann MF, Chang SC, Mouw T, Hollenbeck AR, Schatzkin A, Brinton LA.

Cancer. 2007 Apr 1;109(7):1303-11. Erratum in: Cancer. 2007 Aug 15;110(4):937.

11.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators..

JAMA. 2002 Jul 17;288(3):321-33.

PMID:
12117397
12.

Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.

Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD, Klein L, Manson JE, Martin LW, Robinson J, Wassertheil-Smoller S, Stefanick ML.

Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1108-16. doi: 10.1161/CIRCEP.112.972224.

13.

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators..

JAMA. 2003 May 28;289(20):2651-62.

PMID:
12771112
14.

Comparative cardiovascular effects of different progestins in menopause.

Rosano GM, Fini M.

Int J Fertil Womens Med. 2001 Sep-Oct;46(5):248-56. Review.

PMID:
11720197
15.

Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study.

Prentice RL, Pettinger M, Beresford SA, Wactawski-Wende J, Hubbell FA, Stefanick ML, Chlebowski RT.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1531-7. doi: 10.1158/1055-9965.EPI-08-1209.

16.

Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.

Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O'Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice RL.

JAMA Oncol. 2015 Jun;1(3):296-305. doi: 10.1001/jamaoncol.2015.0494.

PMID:
26181174
17.

Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy.

Rosano G, Vitale C, Spoletini I, Fini M.

Climacteric. 2012 Aug;15(4):299-305. doi: 10.3109/13697137.2012.658899. Review.

PMID:
22424090
18.

KEEPS: The Kronos Early Estrogen Prevention Study.

Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N.

Climacteric. 2005 Mar;8(1):3-12.

PMID:
15804727
19.
20.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee..

JAMA. 2004 Apr 14;291(14):1701-12.

PMID:
15082697
Items per page

Supplemental Content

Support Center